​

Dianthus Therapeutics Ownership | Who Owns Dianthus Therapeutics?

OverviewForecastRevenueFinancialsChart

Dianthus Therapeutics Ownership Summary

Dianthus Therapeutics is owned by 137.55% institutional investors, 0.12% insiders. Fmr is the largest institutional shareholder, holding 17.07% of DNTH shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 4.02% of its assets in Dianthus Therapeutics shares.

DNTH Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockDianthus Therapeutics137.55%0.12%-37.67%
SectorHealthcare Stocks 52.57%12.37%35.07%
IndustryBiotech Stocks 52.24%12.07%35.70%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr8.20M17.07%$799.33M
Blackrock funding, inc. /de4.12M8.59%$401.99M
T. rowe price investment management3.89M8.10%$379.05M
Wellington management group llp3.23M6.72%$314.85M
Vanguard group2.05M5.42%$84.42M
Fairmount funds management2.54M5.28%$247.33M
Price t rowe associates inc /md/2.51M5.24%$245.16M
State street2.36M4.91%$229.80M
Vanguard capital management2.16M4.50%$210.51M
Avidity partners management lp2.10M4.38%$205.12M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Avidity partners management lp2.10M32.85%$205.12M
Fairmount funds management2.54M16.35%$247.33M
Octagon capital advisors lp1.84M16.14%$179.53M
5am venture management365.05K5.26%$14.36M
Silverarc capital management390.00K3.95%$38.02M
Tcg crossover management1.68M3.93%$163.44M
Cormorant asset management, lp750.00K3.75%$73.11M
Vr adviser1.18M3.49%$115.03M
Stempoint capital lp200.85K3.37%$19.58M
Logos global management lp800.00K3.36%$77.98M

Top Buyers

HolderShares% AssetsChange
T. rowe price investment management3.89M0.25%2.60M
Price t rowe associates inc /md/2.51M0.02%1.37M
State street2.36M0.01%958.53K
Blackrock funding, inc. /de4.12M0.01%948.12K
Wellington management group llp3.23M0.05%634.10K

Top Sellers

HolderShares% AssetsChange
Ra capital management---2.61M
Deep track capital, lp---2.23M
Vestal point capital, lp1.18M2.10%-2.02M
Farallon capital management---836.00K
Point72 asset management---643.60K

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company365.96K0.00%365.96K$35.67M
Ikarian capital346.00K1.37%346.00K$13.62M
Westfield capital management co lp314.91K0.10%314.91K$30.70M
Assenagon asset management280.65K0.03%280.65K$27.36M
Emerald advisers247.81K0.57%247.81K$24.16M

Sold Out

HolderChange
Root financial partners-3.00
Montag a & associates-9.00
Creative financial designs inc /adv-10.00
Ameritas advisory services-11.00
Principal securities-11.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202627510.00%66,067,9476.22%1370.51%1822.25%6615.79%
Mar 31, 202677-54.44%6,290,279-87.19%160.10%62-48.33%14-51.72%
Dec 31, 202522-85.23%2,846,620-93.92%70.04%15-84.38%6-82.35%
Sep 30, 202534-67.31%2,900,005-92.58%80.07%22-54.17%7-82.05%
Jun 30, 20251041.96%39,106,7373.69%1090.90%48-3934.48%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S2.20M4.02%-
Vanguard MStar Total Stk Mkt Idx Invest1.66M3.02%5.39K
Vanguard Morn Total Stk Mkt Idx Investor1.65M3.02%77.78K
Vanguard Total Stock Mkt Idx Inv1.65M3.02%77.78K
Fidelity Growth Company Fund1.59M2.91%-1.97K
Vanguard Health Care Inv1.50M2.74%43.45K
State Street® SPDR® S&P® Biotech ETF1.28M2.33%2.94K
iShares Russell 2000 ETF1.20M2.18%-21.22K
T. Rowe Price Small-Cap Stock1.17M2.15%614.06K
T. Rowe Price US Small-Cap Core Equity1.17M2.15%675.11K

Recent Insider Transactions

DateNameRoleActivityValue
Sep 01, 2026Randhawa Simrat EVP, Head of R&DSell$273.49K
Sep 01, 2026Randhawa Simrat EVP, Head of R&DSell$1.42M
Sep 01, 2026Randhawa Simrat EVP, Head of R&DSell$766.59K
Aug 19, 2026Read Simon-Sell$326.55K
Aug 10, 2026McGeorge Anne-Sell$110.64K

Insider Transactions Trends

DateBuySell
2026 Q3-28
2026 Q2-7
2026 Q1-21
2025 Q4-5
2025 Q3-1

DNTH Ownership FAQ

Who Owns Dianthus Therapeutics?

Dianthus Therapeutics shareholders are primarily institutional investors at 137.55%, followed by 0.12% insiders and -37.67% retail investors. The average institutional ownership in Dianthus Therapeutics's industry, Biotech Stocks , is 52.24%, which Dianthus Therapeutics exceeds.

Who owns the most shares of Dianthus Therapeutics?

Dianthus Therapeutics’s largest shareholders are Fmr (8.2M shares, 17.07%), Blackrock funding, inc. /de (4.12M shares, 8.59%), and T. rowe price investment management (3.89M shares, 8.10%). Together, they hold 33.75% of Dianthus Therapeutics’s total shares outstanding.

Does Blackrock own Dianthus Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Dianthus Therapeutics.

Who is Dianthus Therapeutics’s biggest shareholder by percentage of total assets invested?

Avidity partners management lp is Dianthus Therapeutics’s biggest shareholder by percentage of total assets invested, with 32.85% of its assets in 2.1M Dianthus Therapeutics shares, valued at 205.12M$.

Who is the top mutual fund holder of Dianthus Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Dianthus Therapeutics shares, with 4.02% of its total shares outstanding invested in 2.2M Dianthus Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools